STAB1 and B-cell non-Hodgkin lymphoma: Among the different malignancies, the results indicated high expression of STAB1 mRNA in nearly all AML samples and in a subset of the myeloproliferative disease samples (MDS), T- and B-cell lymphoma samples, as well as in pre-B-cell acute lymphoblastic leukemia (Fig. 1B).